TCBP TC BioPharm (Holdings) Plc: Multiplikator forward rega marang pendapatan
The forward P/S ratio allows for an assessment of the asset's value dynamics, with 0.20 serving as the current value of the indicator. TC Biopharm revenues will be based on the implementation of gamma-delta T-cell therapy against leukemia. The company's innovative approach simplifies the mass application of cancer immunotherapy. The stability of R&D processes is guaranteed through a system of grants and the retention of key immunologists.
TC BioPharm Ltd (TCBP) - rincian metrik lan laporan keuangan
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal TC Biopharm|TCBP - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal TC Biopharm|TCBP - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku TC Biopharm|TCBP - Utang jangka dawa|Utang jangka cendhak perusahaan TC BioPharm|Rasio cepet tcbiopharm.com
- rincian asil keuangan lan kelipatan valuasi:
TCBP - Bathi pungkasan|Proyeksi bathi mangsa ngarep TC Biopharm|TCBP - Pangali P/E|Rega marang bathi mangsa ngarep TC BioPharm (Holdings) PLC|TCBP - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan TC Biopharm|TCBP - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan TC BioPharm|TCBP - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan tcbiopharm.com|TCBP - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep TC Biopharm
- data dodolan lan asil:
Analisis komprehensif perusahaan:TCBP (TC BioPharm)
Forward P/S measures the market value of TC Biopharm relative to expected sales volume, allowing for an assessment of investor confidence in management's long-term strategy during the intervals between earnings reports. The trend of this forward revenue multiple reflects the speculative premium on TC Biopharm capital, which depends directly on the commercialization prospects of its available allogeneic gamma-delta T-cell based cancer therapy.
Analisis pesaing
Multiplikator Forward P/S ARGX (argenx)|BioNTech Inc. (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABVX: Multiplikator forward rega marang pendapatan|ADMA Corp - Rasio rega marang pendapatan sing dikarepake|PTGX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan immunovant.com|Multiplikator forward rega marang pendapatan KNSA|GRFS: Rega forward marang dodolan|Multiplikator Forward P/S ADPT|Rasio rega marang prakiraan pendapatan CLDX (Celldex Corp)|Multiplikator Forward P/S AUPH (Aurinia Pharmaceuticals)|Rasio kapitalisasi marang dodolan sing dikarepake biocryst.com (BCRX)|VERA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Dianthus Therapeutics Inc|Pharvaris Corp (PHVS) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ABCL (AbCellera Corp)|TRML (Tourmaline Bio, Inc.) - Multiplikator Forward P/S|PGEN: Rega forward marang dodolan|Multiplikator Forward P/S PHAR|Multiplikator Forward P/S Nektar Therapeutics Inc (NKTR)|Rasio rega marang prakiraan pendapatan Upstream Bio Corp UPB|Rega forward marang dodolan ZBIO|IMNM - Rasio rega marang prakiraan pendapatan|gossamerbio.com (GOSS) - Multiplikator forward rega marang pendapatan|KALV (KalVista Pharmaceuticals, Inc.) - Multiplikator forward rega marang pendapatan|SEPN: Rasio rega marang pendapatan sing dikarepake|PVLA (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Savara Pharma (SVRA)|Multiplikator Forward P/S RIGL|Rasio rega marang prakiraan pendapatan ANAB (anaptysbio.com)|Rasio rega marang prakiraan pendapatan Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Rega mangsa ngarep marang pendapatan|RAPT - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan JBIO|ACRS: Multiplikator Forward P/S|kyvernatx.com - Rega forward marang dodolan|TLSA (Tiziana Life Sciences Ltd) - Multiplikator Forward P/S|Multiplikator Forward P/S Cabaletta Bio Inc.|Rasio rega marang prakiraan pendapatan Ventyx Bio (VTYX)|THTX (Theratechnologies, Inc) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Avalo Therapeutics, Inc AVTX|ELDN - Multiplikator forward rega marang pendapatan|Agenus Inc. - Multiplikator Forward P/S|CLYM - Multiplikator Forward P/S|ZURA (Zura Bio Limited) - Multiplikator forward rega marang pendapatan|aTyr Pharmaceuticals - Rega forward marang dodolan|ADAG (Adagene Inc) - Multiplikator Forward P/S|Ikena Oncology, Inc. (IMA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Shattuck Labs, Inc. (STTK)|Multiplikator forward rega marang pendapatan equilliumbio.com EQ|Rasio rega marang prakiraan pendapatan Connect Biopharma Holdings Limited CNTB|IMUX - Multiplikator forward rega marang pendapatan|ATRA: Multiplikator forward rega marang pendapatan|IFRX - Multiplikator Forward P/S|X4 Pharmaceuticals, Inc. (XFOR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan ACET|CELU (Celularity Inc) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep INmune Bio Corporation INMB|Multiplikator forward rega marang pendapatan BRNS (Barinthus Biotherapeutics)|Rasio rega marang pendapatan sing dikarepake KZR|Multiplikator Forward P/S SABS (SAB Biotherapeutics, Inc.)|AKTX - Multiplikator forward rega marang pendapatan|ENLV: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QTTB (Q32 Bio Inc.)|GOVX: Multiplikator Forward P/S|EDSA (edesabiotech.com) - Rasio rega marang prakiraan pendapatan|IBIO (iBio) - Multiplikator Forward P/S|Carisma Tx (CARM) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan XTL Biopharmaceuticals, Ltd. (XTLB)|BOLT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan HCW Biologics HCWB|APVO (Aptevo Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|AIM ImmunoTech - Multiplikator Forward P/S|Rega forward marang dodolan ADTX (Aditxt)|GRI: Multiplikator Forward P/S|XORTX Corp (XRTX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Vyome Holdings Inc|REVB: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Indaptus Therapeutics, Inc. (INDP)|Multiplikator forward rega marang pendapatan Scinai Immunotherapeutics Ltd SCNI|CalciMedica - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake AFMD (Affimed NV)|Allakos Therapeutics - Multiplikator Forward P/S|HOOKIPA Pharma Inc. (HOOK) - Multiplikator forward rega marang pendapatan|IGMS: Multiplikator Forward P/S|ITOS (iTeos Therapeutics Inc) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Ocean Bio|Third Harmonic Bio Inc - Rega mangsa ngarep marang pendapatan
